This provides further evidence for the value of FLT3 targeting in B-ALL, in particular since other investigators implicated FLT3 to be expressed on leukemic stem cells in ALL [32] and that FLT3 may associate with B-ALL cell resistance to conventional therapy [33]. Here, FLT3 is linked to acute lymphoblastic leukemia.